PUBLIC COMPANY
saveStemline Therapeutics Inc
updated 12d ago
community read0 votes
🐶 often sniffed alongside
top 7pipeline
5
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
2Phase 12Phase 21Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast CancerCapivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.onclive · 3mo ago
comments(0)
5-min edit window · permanent after that